Kidney international最新文献

{"title":"journal club","authors":"","doi":"10.1016/j.kint.2026.04.014","DOIUrl":"10.1016/j.kint.2026.04.014","url":null,"abstract":"","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"110 1","pages":"Pages 17-18"},"PeriodicalIF":21.8,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148380114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proteogenomic dissection of kidney disease and cardiovascular-kidney-metabolic syndrome","authors":"Haikuo Li","doi":"10.1016/j.kint.2025.12.038","DOIUrl":"10.1016/j.kint.2025.12.038","url":null,"abstract":"","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"110 1","pages":"Pages 19-22"},"PeriodicalIF":21.8,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146160152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A missense mutation in the SAA1 protein causing hereditary amyloid A amyloidosis","authors":"Nelson Leung, Aleš Hnízda, Ellen D. McPhail, Surendra Dasari, Lenka Nosková, Petr Vyleťal, Jiří Mikšátko, Lenka Piherová, Tereza Kmochová, Dita Mušálková, Zdislava Vaníčková, Martin Radina, Tomáš Zima, Kateřina Hodaňová, Hana Hartmannová, Viktor Stránecký, Samih H. Nasr, Romana Ryšavá, Martina Živná, Jakub Sikora, Stanislav Kmoch","doi":"10.1016/j.kint.2026.01.035","DOIUrl":"10.1016/j.kint.2026.01.035","url":null,"abstract":"","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"110 1","pages":"Pages 255-259"},"PeriodicalIF":21.8,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147518491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Individual participant-level analysis of four randomized clinical trials examined therapeutic effects of blood pressure lowering on hierarchical kidney outcome using win statistics","authors":"Yezhou Liu,&nbsp;Yizhen Lyu,&nbsp;Yamei Liu,&nbsp;Jiaheng Zhang,&nbsp;Zhaojie Song,&nbsp;Kangyu Chen,&nbsp;Zhixin Jiang,&nbsp;Hong Yan,&nbsp;Tao Chen,&nbsp;Chao Li","doi":"10.1016/j.kint.2026.02.032","DOIUrl":"10.1016/j.kint.2026.02.032","url":null,"abstract":"<div><h3>Introduction</h3><div>Despite established cardiovascular benefits, the effects of intensive blood pressure (BP) lowering and specific agents on kidney function remain debated. Here, we assessed these effects using a validated hierarchical composite kidney endpoint (HCE) that prioritizes clinical severity.</div></div><div><h3>Methods</h3><div>This post hoc analysis used individual-level data from four large randomized clinical trials: SPRINT, ACCORD-BP, SHEP, and ALLHAT. The seven-tier HCE ranked components by clinical severity: all-cause mortality, kidney failure, estimated glomerular filtration rate (eGFR) under 15 mL/min/1.73m², eGFR declines of 57%/50%/40% or more, and three-year total eGFR slope. We estimated Win Odds (WO) for all randomized participants, with missing outcomes handled as ties.</div></div><div><h3>Results</h3><div>A total of 61,248 participants were included with median follow-ups of 46 to 60 months across trials. Intensive BP treatment yielded unfavorable WO compared with standard treatment in SPRINT (WO, 0.61 [95% confidence interval, 0.58–0.64]) and ACCORD-BP (WO, 0.64 [0.59–0.68]. In SHEP, chlorthalidone was inferior to placebo (WO, 0.89 [0.84–0.95]). In ALLHAT, doxazosin (WO, 1.29 [1.25–1.33]) and amlodipine (WO, 1.38 [1.34–1.42]) outperformed chlorthalidone, while lisinopril was slightly less favorable (WO, 0.96 [0.93–0.98]). The eGFR slope component contributed over 50% to the win statistics across trials. Results were broadly consistent across subgroups and sensitivity analyses.</div></div><div><h3>Conclusions</h3><div>Our hierarchical analysis indicated that intensive BP lowering and chlorthalidone were associated with less favorable mid-term eGFR trajectories. Driven largely by the eGFR slope, which represents a sensitive signal of kidney reserve depletion, our findings support monitoring kidney function to optimize the balance between cardiovascular protection and kidney preservation.</div></div><div><h3>Trial Registration</h3><div>Registered at <span><span>Clinicaltrials.gov</span><svg><path></path></svg></span> with study numbers NCT01206062, NCT00000620, NCT00000514, and NCT00000542.</div></div>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"110 1","pages":"Pages 178-189"},"PeriodicalIF":21.8,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147535716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In memoriam: Raymond Ardaillou (1930–2026)","authors":"Pierre Ronco,&nbsp;Christos Chatziantoniou,&nbsp;Jean-Claude Dussaule","doi":"10.1016/j.kint.2026.04.015","DOIUrl":"10.1016/j.kint.2026.04.015","url":null,"abstract":"","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"110 1","pages":"Pages 5-7"},"PeriodicalIF":21.8,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148582409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Green dialysis: environmentally sustainable care, growth, and innovation: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","authors":"Katherine A. Barraclough,&nbsp;Nathan Berman-Parks,&nbsp;Vivekanand Jha,&nbsp;Giorgina B. Piccoli,&nbsp;Caroline Stigant,&nbsp;Benjamin Talbot,&nbsp;Faissal Tarrass,&nbsp;Michael Cheung,&nbsp;Jennifer M. King,&nbsp;Morgan E. Grams,&nbsp;Michel Jadoul,&nbsp;Jennifer E. Flythe","doi":"10.1016/j.kint.2026.01.015","DOIUrl":"10.1016/j.kint.2026.01.015","url":null,"abstract":"<div><div>Hemodialysis, hemodiafiltration, and peritoneal dialysis are among the most resource-intensive medical therapies, owing to their high energy and water consumption, heavy reliance on disposable materials, and frequent, recurring delivery. Although “green dialysis” initiatives have been adopted in some regions, broader implementation is needed, together with the development of new technologies and care models to further mitigate the environmental impact of dialysis. In April 2025, Kidney Disease: Improving Global Outcomes (KDIGO) held the Controversies Conference on Green Dialysis: Environmentally Sustainable Care, Growth, and Innovation. Participants included physicians, nurses, patients, and engineers who examined how existing hemodialysis (in-center and home) and peritoneal dialysis practices might be optimized to promote environmental sustainability. Additionally, opportunities for green innovations in dialysis procedures and technologies were identified. Recognizing the need for urgent and coordinated action among patients, clinicians, and organizations, participants also discussed how industry, policy, and regulations could support embedding environmental sustainability within dialysis care.</div></div>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"110 1","pages":"Pages 42-60"},"PeriodicalIF":21.8,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146227254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Roles of WNK1 and mTORC2 in aldosterone-independent regulation of potassium secretion in the distal nephron","authors":"Bidisha Saha,&nbsp;Enzo Takagi,&nbsp;Cheng-Biao Zhang,&nbsp;John Demko,&nbsp;Robert Weber,&nbsp;Ken Kaseda,&nbsp;Jian Xie,&nbsp;Anna Manis,&nbsp;Deise Carla Almeida Leite Dellova,&nbsp;Mads Vaarby Sørensen,&nbsp;Chou-Long Huang,&nbsp;Shigeru Shibata,&nbsp;Wen-Hui Wang,&nbsp;David Pearce","doi":"10.1016/j.kint.2026.03.014","DOIUrl":"10.1016/j.kint.2026.03.014","url":null,"abstract":"<div><h3>Introduction</h3><div>Precise regulation of kidney potassium excretion is essential for maintaining plasma potassium concentration within narrow limits in the face of wide variations in intake. Aldosterone has long been considered the key regulator of tubule potassium secretion. However, increasing evidence suggests that it plays a relatively limited role over a wide range of potassium ingestion. Here we investigated the roles of WNK1 kinase and the mTORC2 regulatory complex in potassium secretion in the distal nephron of mice.</div></div><div><h3>Methods</h3><div>We generated knockout (KO) mice where alternatively mTORC2 or the potassium-sensitive kinase, WNK1, were selectively disrupted in the late distal convoluted tubule and early connecting tubule (DCT2/CNT_e), an important site of potassium secretion. KO mice were subjected to an acute increase in dietary potassium, after which fluid and electrolyte parameters were measured, and subcellular localization and activity of key ion channels were assessed using immunofluorescence and patch clamp, respectively. Phosphorylation state of mTORC2 targets was determined using Western blot.</div></div><div><h3>Results</h3><div>In mice lacking mTORC2 in the DCT2/CNT_e, urinary potassium excretion failed to increase adequately in response to high potassium intake, while sodium, chloride and net urine output were excessive, resulting in hyperkalemia and fluid volume wasting. Immunofluorescence and patch clamp revealed that active apical membrane sodium channels (αENaC) in DCT2/CN_e failed to increase. Furthermore, KO mice lacking WNK1 in the DCT2/CNT_e similarly have diminished potassium excretion and diminished mTORC2-dependent phosphorylation of key targets involved in potassium secretion.</div></div><div><h3>Conclusions</h3><div>These findings strongly support the idea that a WNK1-mTORC2-dependent signaling pathway acts selectively in the DCT2/CNT_e to regulate potassium secretion in an aldosterone-independent manner.</div></div>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"110 1","pages":"Pages 161-177"},"PeriodicalIF":21.8,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147743857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"KDIGO Life Cycle of Guideline Development Series Part 5: Guideline updates and a living model for the future.","authors":"Benjamin Lazarus,Laia Oliveras,Amara Sarwal,Elie Akl,Chris Carmona,Imuetinyan Edeki,Jitendra Meena,Joyce Popoola,Robin Vernooij,Gihad Nesrallah,Amy Earley,Reem A Mustafa","doi":"10.1016/j.kint.2026.06.016","DOIUrl":"https://doi.org/10.1016/j.kint.2026.06.016","url":null,"abstract":"New evidence relevant to the management of kidney disease is constantly being generated, underscoring the need for timely, rigorous, and trustworthy clinical practice guidelines that translate evidence into improved patient outcomes. The accelerating pace of innovation presents a challenge as well as an opportunity for rapid and seamless translation. This paper extends the work of earlier papers in the methodology series by describing the methods that Kidney Disease: Improving Global Outcomes (KDIGO) uses to prioritize topics and update existing guidelines and recommendations. Finally, we examine a living guideline framework, balancing the promise of more agile, up-to-date recommendations with the practical and methodological challenges inherent to continuous evidence integration.","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"13 1","pages":""},"PeriodicalIF":19.6,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148365246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reversal of advanced diabetic kidney disease in mice treated with a monoclonal anti-VEGFR1 antibody","authors":"Zhonghua Qi ,&nbsp;Ying Tang ,&nbsp;Johnny Eugene Croy ,&nbsp;Jonathan M. Wilson ,&nbsp;Kathleen M. Heinz-Taheny ,&nbsp;Kelly M. Credille ,&nbsp;Asim Bikash Dey ,&nbsp;Tamer Coskun ,&nbsp;Yan Ding ,&nbsp;Dianna Jaqua ,&nbsp;Yuan Su ,&nbsp;Olivia Hope Vitale ,&nbsp;Matthew J. Hamang ,&nbsp;Arindam Majumdar ,&nbsp;Elaine M. Conner ,&nbsp;Ina Maria Schiessl ,&nbsp;Janos Peti-Peterdi ,&nbsp;Georgina Gyarmati ,&nbsp;James T. Raymond ,&nbsp;Kevin L. Duffin ,&nbsp;Matthew D. Breyer","doi":"10.1016/j.kint.2026.03.016","DOIUrl":"10.1016/j.kint.2026.03.016","url":null,"abstract":"<div><h3>Introduction</h3><div>Diabetic kidney disease (DKD) continues to be the major cause of kidney failure, and its treatment is of key importance. Targeting VEGF-A has yielded conflicting results in DKD models. Here, we investigated the potential benefit of targeting VEGF-A or its receptors for the treatment of advanced mouse DKD.</div></div><div><h3>Methods</h3><div>Our studies tested the effects of neutralizing antibodies targeting VEGF-A, VEGFR2, and VEGFR1 on kidney function and histopathology, in 4 different mouse models of DKD and chronic kidney disease (CKD).</div></div><div><h3>Results</h3><div>Unlike previous reports, blocking VEGF-A using an anti–VEGF-A monoclonal antibody worsened albuminuria and kidney injury in uninephrectomized (unix) diabetic db/db mice. Similar results were seen with the anti-VEGFR2 antibody (DC101). In contrast, antibody MF1, a VEGFR1 selective monoclonal blocking antibody, dramatically decreased albuminuria, improved kidney function, and reduced renal histological injury in the remnant kidney mice, unix db/db mice with or without renin-AAV injection, and eNOS^–/–db/db hypertensive mice. MF1 also improved animal survival. MF1 benefit persisted in albuminuric transgenic mice lacking the VEGFR1 cytoplasmic tyrosine kinase domain. In renin-AAV unix db/db mice with advanced DKD, we observed improved survival, reduced serum creatinine, and regression of established kidney histological changes following delayed MF1 treatment. VEGFR1 antibody increased circulating placental growth factor and VEGF-A as well as phosphorylation of kidney VEGFR2. MF1 reduced blood pressure in diabetic eNOS^–/– mice and acutely increased the glomerular filtration rate in db/db mice.</div></div><div><h3>Conclusions</h3><div>Our studies demonstrate that blocking VEGFR1 improved kidney function and microvascular structure in models of progressive CKD. VEGFR1 blockade provided a promising novel therapeutic approach to reverse DKD progression.</div></div>","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"110 1","pages":"Pages 99-114"},"PeriodicalIF":21.8,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147751412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neglected no longer: lymphatic vessels in the rejecting allograft","authors":"Griffith B. Perkins,&nbsp;Maarten Naesens","doi":"10.1016/j.kint.2026.01.012","DOIUrl":"10.1016/j.kint.2026.01.012","url":null,"abstract":"","PeriodicalId":17801,"journal":{"name":"Kidney international","volume":"110 1","pages":"Pages 23-25"},"PeriodicalIF":21.8,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147276620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}